What current CBD evidence can and cannot establish
Reviewed by executive management. September 16, 2026. Scientific review pending.
Evidence about CBD is often broader, weaker or less directly relevant than a headline suggests. The summaries below separate what was studied from what can be concluded about Micelle 60.
Important evidence context. Micelle 60 and FDA-approved prescription cannabidiol are separate products. No clinical, pharmacokinetic, exposure, efficacy, safety or comparability bridge has been established between them. Micelle 60 is not FDA approved, and no clinical benefit or product-specific safety profile has been established for it.
How we review this information
These pages are reviewed and approved by executive management and have been submitted to our Chief Scientific Officer for scientific review. Each page will show her name and the date once she has signed it. Each claim-bearing page identifies its sources, evidence limitations and the date the evidence was last checked. Draft or incomplete pages remain unpublished.
Anxiety
Small, heterogeneous CBD studies using different doses and treatment schedules have produced mixed results. A 2026 synthesis of randomized cannabinoid trials did not establish benefit for anxiety symptoms; its pooled analysis was not CBD-only. [8] No CBD product is FDA approved for anxiety. [1] Micelle 60 has not been studied in clinical trials.Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Wilson J, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. The Lancet Psychiatry. 2026;13(4):304–315. doi:10.1016/S2215-0366(26)00015-5. With June 16, 2026 correction. Last checked: .
Sleep
Sleepiness as an adverse effect is not treatment of insomnia. In a 30-person pilot trial, 150 mg nightly CBD was similar to placebo on most sleep outcomes. A 2025 review found no significant improvement in sleep quality in its CBD-only subgroup. No CBD product is FDA approved for insomnia, and no benefit has been established for Micelle 60. [9–10]Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Narayan AJ, et al. Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. Journal of Clinical Sleep Medicine. 2024;20(5):753–763. doi:10.5664/jcsm.10998.; da Silva GHS, et al. Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. Sleep Medicine Reviews. 2025;84:102156. doi:10.1016/j.smrv.2025.102156. Last checked: .
Chronic pain
Most favorable pain evidence concerns THC-containing products. In the 2025 AHRQ review, purified or synthetic oral CBD alone was not associated with less pain or better function than placebo. No CBD product is FDA approved for pain, and these findings do not establish the effects of Micelle 60. [11]Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Chou R, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update. AHRQ Comparative Effectiveness Review No. 250; Publication No. 25-EHC036. July 2025. Last checked: .
Cancer
Laboratory and animal findings do not establish cancer treatment in people. Human evidence has not established that CBD treats cancer or slows its progression. ASCO recommends against using cannabis or cannabinoids as cancer-directed treatment outside a clinical trial. Prescription cannabinoid drugs used in oncology are for specified chemotherapy-related nausea and vomiting—not cancer treatment—and they are not Micelle 60. [12]Source: Braun IM, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(13):1575–1593. doi:10.1200/JCO.23.02596. Last checked: .
Brain effects
CBD does not cause the characteristic intoxication associated with delta-9 THC, but it is not neurologically inactive. FDA-approved prescription cannabidiol can cause somnolence and sedation. Those findings do not establish how often this occurs with Micelle 60. [2]Source: Jazz Pharmaceuticals, Inc. EPIDIOLEX® (cannabidiol) oral solution: Full Prescribing Information. Revised May 2026. DailyMed, U.S. National Library of Medicine. Last checked: .
Interactions
The prescription-cannabidiol label documents clinically relevant interactions involving clobazam, valproate, everolimus, stiripentol and CYP2C19 substrates such as clopidogrel, plus possible additive sedation with alcohol or other central nervous system depressants. This is not a complete list. These data do not quantify Micelle 60’s interaction risk. [2]Source: Jazz Pharmaceuticals, Inc. EPIDIOLEX® (cannabidiol) oral solution: Full Prescribing Information. Revised May 2026. DailyMed, U.S. National Library of Medicine. Last checked: .
More milligrams
More is not necessarily better. No effective dose has been established for Micelle 60. With prescription cannabidiol, higher doses were associated with more adverse reactions, and liver-enzyme elevations and somnolence or sedation were dose-related. [2]Source: Jazz Pharmaceuticals, Inc. EPIDIOLEX® (cannabidiol) oral solution: Full Prescribing Information. Revised May 2026. DailyMed, U.S. National Library of Medicine. Last checked: .
Product transfer
Findings depend on the exact product, formulation, dose, route, population and condition. Results cannot be transferred to Micelle 60 without appropriate bridging evidence.
Full spectrum
The “entourage effect” remains a hypothesis; a general clinical advantage of full-spectrum products over isolate has not been established. “Full spectrum” is not a uniform federal quality standard, and products using the term may contain THC and other active constituents.
Natural means safe
Natural origin does not establish safety. Prescription-dose cannabidiol risks include sedation, diarrhea, reduced appetite, liver-test abnormalities and interactions. Their frequency and magnitude with Micelle 60 are unknown. [2, 7]Source: Jazz Pharmaceuticals, Inc. EPIDIOLEX® (cannabidiol) oral solution: Full Prescribing Information. Revised May 2026. DailyMed, U.S. National Library of Medicine.; Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Internal Medicine. 2025;185(9):1070–1078. doi:10.1001/jamainternmed.2025.2366. Last checked: .
“CBD is FDA approved”
FDA has approved one prescription drug containing purified CBD for specified seizure indications. That approval does not extend to CBD generally or Micelle 60. [1]Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Last checked: .
“60 mg is a clinically proven dose”
No study cited here establishes that Micelle 60 treats anxiety, insomnia, pain, cancer or another condition.
For questions about your own health, speak to your care team.
Sources: [1–2, 7–12]. Evidence last checked September 16, 2026.Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Jazz Pharmaceuticals, Inc. EPIDIOLEX® (cannabidiol) oral solution: Full Prescribing Information. Revised May 2026. DailyMed, U.S. National Library of Medicine.; Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Internal Medicine. 2025;185(9):1070–1078. doi:10.1001/jamainternmed.2025.2366.; Wilson J, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. The Lancet Psychiatry. 2026;13(4):304–315. doi:10.1016/S2215-0366(26)00015-5. With June 16, 2026 correction.; Narayan AJ, et al. Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. Journal of Clinical Sleep Medicine. 2024;20(5):753–763. doi:10.5664/jcsm.10998.; da Silva GHS, et al. Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. Sleep Medicine Reviews. 2025;84:102156. doi:10.1016/j.smrv.2025.102156.; Chou R, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update. AHRQ Comparative Effectiveness Review No. 250; Publication No. 25-EHC036. July 2025.; Braun IM, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(13):1575–1593. doi:10.1200/JCO.23.02596. Last checked: .